KING OF PRUSSIA, PA — SEED Therapeutics, Inc. said it will present research on an RBM39 degrader targeting neuroblastoma at the 2026 American Association for Cancer Research annual meeting in San Diego.
The company said the poster presentation will highlight anticancer activity of the RBM39 degrader and evaluate MYC and CDKN2A/B as potential biomarkers for treatment response.
The presentation is scheduled for April 21 from 2 p.m. to 5 p.m. PT in Poster Section 15 at the San Diego Convention Center as part of the “Experimental and Molecular Therapeutics” session.
The research will be presented by James Finn and colleagues as part of a session focused on proximity-induced drug discovery.
SEED Therapeutics is a clinical-stage biotechnology company developing small-molecule therapies designed to degrade disease-related proteins.
The company said its research platform focuses on targeted protein degradation and includes multiple programs across oncology and other disease areas.
SEED was co-founded by researchers including Avram Hershko, Lan Huang, Ning Zheng and Michele Pagano.
Eli Lilly and Co. and Eisai Co., Ltd. are investors and collaborators supporting the company’s research efforts.
Support the local news that supports Chester County. MyChesCo delivers reliable, fact-based reporting and essential community resources—free for everyone. If you value that, click here to become a patron today.